Thyroxine Micro Pellets MUPS
Thalidomide was introduced as a sedative drug in the late 1950s and typically used to cure morning sickness. In 1961, it was withdrawn due to teratogenicity andneuropathy.
There is now a growing clinical interest in thalidomide, and it is introduced as an immunomodulatory agent used primarily, combined with dexamethasone, to treat multiple myeloma.
The drug is a potent teratogen in zebrafish, chickens, rabbits and primates including humans: severe birth defects may result if the drug is taken during pregnancy.
Thalidomide was sold in a number of countries across the world from 1957 until 1961 when it was withdrawn from the market after being found to be a cause of birth defects in what has been called "one of the biggest medical tragedies of modern times". It is not known exactly how many worldwide victims of the drug there have been, although estimates range from 10,000 to 20,000.
Since then thalidomide has been found to be a valuable treatment for a number of medical conditions and it is being prescribed again in a number of countries, although its use remains controversial, including its testing in the developing world. The thalidomide tragedy led to much stricter testing being required for drugs and pesticides before they can be licensed.
Thalidomide Micro Pellets - Multiple Unit Particle System (MUPS)
Thalidomide Micro Granules - Multiple Unit Particle System (MUPS)